269 related articles for article (PubMed ID: 28504970)
1. Osteoclast proton pump regulator Atp6v1c1 enhances breast cancer growth by activating the mTORC1 pathway and bone metastasis by increasing V-ATPase activity.
McConnell M; Feng S; Chen W; Zhu G; Shen D; Ponnazhagan S; Deng L; Li YP
Oncotarget; 2017 Jul; 8(29):47675-47690. PubMed ID: 28504970
[TBL] [Abstract][Full Text] [Related]
2. Silencing of atp6v1c1 prevents breast cancer growth and bone metastasis.
Feng S; Zhu G; McConnell M; Deng L; Zhao Q; Wu M; Zhou Q; Wang J; Qi J; Li YP; Chen W
Int J Biol Sci; 2013; 9(8):853-62. PubMed ID: 24155661
[TBL] [Abstract][Full Text] [Related]
3. Atp6v1c1 may regulate filament actin arrangement in breast cancer cells.
Cai M; Liu P; Wei L; Wang J; Qi J; Feng S; Deng L
PLoS One; 2014; 9(1):e84833. PubMed ID: 24454753
[TBL] [Abstract][Full Text] [Related]
4. Atp6v1c1 is an essential component of the osteoclast proton pump and in F-actin ring formation in osteoclasts.
Feng S; Deng L; Chen W; Shao J; Xu G; Li YP
Biochem J; 2009 Jan; 417(1):195-203. PubMed ID: 18657050
[TBL] [Abstract][Full Text] [Related]
5. Targeting Atp6v1c1 Prevents Inflammation and Bone Erosion Caused by Periodontitis and Reveals Its Critical Function in Osteoimmunology.
Li S; Hao L; Wang L; Lu Y; Li Q; Zhu Z; Shao JZ; Chen W
PLoS One; 2015; 10(8):e0134903. PubMed ID: 26274612
[TBL] [Abstract][Full Text] [Related]
6. The ATPase subunit of ATP6V1C1 inhibits autophagy and enhances radiotherapy resistance in esophageal squamous cell carcinoma.
Yao X; Chen H; Xu B; Lu J; Gu J; Chen F; Ju M; Sun X
Gene; 2021 Feb; 768():145261. PubMed ID: 33183740
[TBL] [Abstract][Full Text] [Related]
7. Regulation of V-ATPase assembly and function of V-ATPases in tumor cell invasiveness.
McGuire C; Cotter K; Stransky L; Forgac M
Biochim Biophys Acta; 2016 Aug; 1857(8):1213-1218. PubMed ID: 26906430
[TBL] [Abstract][Full Text] [Related]
8. C1 Silencing Attenuates Inflammation and Alveolar Bone Resorption in Endodontic Disease.
Wang Y; Chen W; Hao L; McVicar A; Wu J; Gao N; Liu Y; Li YP
J Endod; 2019 Jul; 45(7):898-906. PubMed ID: 31104818
[TBL] [Abstract][Full Text] [Related]
9. Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.
Xu J; Cheng T; Feng HT; Pavlos NJ; Zheng MH
Histol Histopathol; 2007 Apr; 22(4):443-54. PubMed ID: 17290355
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.
Marino S; Bishop RT; Mollat P; Idris AI
Calcif Tissue Int; 2018 Aug; 103(2):206-216. PubMed ID: 29455416
[TBL] [Abstract][Full Text] [Related]
11. Activity-independent targeting of mTOR to lysosomes in primary osteoclasts.
Wang A; Carraro-Lacroix LR; Owen C; Gao B; Corey PN; Tyrrell P; Brumell JH; Voronov I
Sci Rep; 2017 Jun; 7(1):3005. PubMed ID: 28592812
[TBL] [Abstract][Full Text] [Related]
12. Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption.
Wu H; Xu G; Li YP
J Bone Miner Res; 2009 May; 24(5):871-85. PubMed ID: 19113919
[TBL] [Abstract][Full Text] [Related]
13. Isoform-specific gene disruptions reveal a role for the V-ATPase subunit a4 isoform in the invasiveness of 4T1-12B breast cancer cells.
McGuire CM; Collins MP; Sun-Wada G; Wada Y; Forgac M
J Biol Chem; 2019 Jul; 294(29):11248-11258. PubMed ID: 31167791
[TBL] [Abstract][Full Text] [Related]
14. AGPAT9 suppresses cell growth, invasion and metastasis by counteracting acidic tumor microenvironment through KLF4/LASS2/V-ATPase signaling pathway in breast cancer.
Fan SH; Wang YY; Wu ZY; Zhang ZF; Lu J; Li MQ; Shan Q; Wu DM; Sun CH; Hu B; Zheng YL
Oncotarget; 2015 Jul; 6(21):18406-17. PubMed ID: 26110566
[TBL] [Abstract][Full Text] [Related]
15. Lactoferrin selectively triggers apoptosis in highly metastatic breast cancer cells through inhibition of plasmalemmal V-H+-ATPase.
Pereira CS; Guedes JP; Gonçalves M; Loureiro L; Castro L; Gerós H; Rodrigues LR; Côrte-Real M
Oncotarget; 2016 Sep; 7(38):62144-62158. PubMed ID: 27556694
[TBL] [Abstract][Full Text] [Related]
16. VD
Santos JM; Hussain F
J Nutr Biochem; 2019 Aug; 70():185-193. PubMed ID: 31229911
[TBL] [Abstract][Full Text] [Related]
17. CERS2 suppresses tumor cell invasion and is associated with decreased V-ATPase and MMP-2/MMP-9 activities in breast cancer.
Fan SH; Wang YY; Lu J; Zheng YL; Wu DM; Zhang ZF; Shan Q; Hu B; Li MQ; Cheng W
J Cell Biochem; 2015 Apr; 116(4):502-13. PubMed ID: 25213553
[TBL] [Abstract][Full Text] [Related]
18. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGFβ/CTGF Axis.
Hinz N; Baranowsky A; Horn M; Kriegs M; Sibbertsen F; Smit DJ; Clezardin P; Lange T; Schinke T; Jücker M
Cells; 2021 Feb; 10(2):. PubMed ID: 33670586
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic inhibition of vacuolar H+ ATPase reduces physiologic and oncogenic Notch signaling.
Kobia F; Duchi S; Deflorian G; Vaccari T
Mol Oncol; 2014 Mar; 8(2):207-20. PubMed ID: 24309677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
